Sinovac Biotech (SVA) said Monday that it has begun enrollment in a late-stage study of its investigational bivalent vaccine targeting Hand, Foot, and Mouth Disease, or HFMD, caused by enterovirus 71 and coxsackievirus 16.
The company said the trial will evaluate the potential vaccine's efficacy, safety, and immune response in children aged 6 to 71 months.
Sinovac said it is also developing a tetravalent vaccine targeting four major enteroviruses, which was recently approved for clinical trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.